share_log

JP Morgan Maintains Overweight on Intra-Cellular Therapies, Raises Price Target to $81

Benzinga ·  Aug 21 22:13  · Ratings

JP Morgan analyst Jessica Fye maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Overweight and raises the price target from $79 to $81.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment